Harrow (NASDAQ:HROW) Coverage Initiated at HC Wainwright

Research analysts at HC Wainwright started coverage on shares of Harrow (NASDAQ:HROW) in a note issued to investors on Thursday, MarketBeat Ratings reports. The brokerage set a “buy” rating and a $57.00 price target on the stock. HC Wainwright’s price target indicates a potential upside of 83.81% from the company’s current price.

Separately, B. Riley dropped their price target on shares of Harrow from $73.00 to $69.00 and set a “buy” rating on the stock in a research note on Wednesday, December 4th.

Harrow Price Performance

Shares of NASDAQ HROW opened at $31.01 on Thursday. The stock has a fifty day moving average price of $35.00 and a 200 day moving average price of $39.58. Harrow has a 1-year low of $9.30 and a 1-year high of $59.23. The company has a debt-to-equity ratio of 3.23, a current ratio of 1.55 and a quick ratio of 1.44. The company has a market cap of $1.10 billion, a PE ratio of -32.99 and a beta of 0.69.

Institutional Investors Weigh In On Harrow

Several institutional investors have recently made changes to their positions in HROW. HighTower Advisors LLC lifted its stake in shares of Harrow by 13.8% in the fourth quarter. HighTower Advisors LLC now owns 10,127 shares of the company’s stock valued at $340,000 after purchasing an additional 1,227 shares during the period. AlphaQuest LLC increased its holdings in Harrow by 452.8% in the fourth quarter. AlphaQuest LLC now owns 3,527 shares of the company’s stock valued at $118,000 after buying an additional 2,889 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Harrow by 1.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 255,218 shares of the company’s stock valued at $8,563,000 after acquiring an additional 3,589 shares during the period. Versor Investments LP purchased a new stake in shares of Harrow during the 4th quarter worth approximately $305,000. Finally, Bank of New York Mellon Corp grew its holdings in shares of Harrow by 8.4% in the 4th quarter. Bank of New York Mellon Corp now owns 86,447 shares of the company’s stock worth $2,900,000 after acquiring an additional 6,690 shares during the period. 72.76% of the stock is currently owned by hedge funds and other institutional investors.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.